# Structural insights into the triple agonism at GLP-1R, GIPR and GCGR manifested by retatrutide.

> PubMed lists PMID 39019866 in Cell discovery as Letter, with publication-date metadata of 2024-07-17 (day precision). PeptideScanner associated the retained record with the identity slug retatrutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-39019866-retatrutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2024-07-20
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-39019866-retatrutide/
- JSON record: https://peptidescanner.com/evidence/v1/objects/pubmed-pmid-39019866-retatrutide-v1.json
- Content SHA-256: `c936a9e916f15ffba7e1b7f3ffc8978af24ad29ba3dd29973f95a974a2bba6cd`

## Claims and source pins

### Headline

Structural insights into the triple agonism at GLP-1R, GIPR and GCGR manifested by retatrutide. ([`pubmed-observation-pmid-39019866-2024-07-20-497b93ace79d`](#source-pubmed-observation-pmid-39019866-2024-07-20-497b93ace79d))

### Summary

PubMed lists PMID 39019866 in Cell discovery as Letter, with publication-date metadata of 2024-07-17 (day precision). PeptideScanner associated the retained record with the identity slug retatrutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-39019866-2024-07-20-497b93ace79d`](#source-pubmed-observation-pmid-39019866-2024-07-20-497b93ace79d))

### Paragraph 1

PubMed lists PMID 39019866 in Cell discovery as Letter, with publication-date metadata of 2024-07-17 (day precision). PeptideScanner associated the retained record with the identity slug retatrutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-39019866-2024-07-20-497b93ace79d`](#source-pubmed-observation-pmid-39019866-2024-07-20-497b93ace79d))

### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-39019866-2024-07-20-497b93ace79d`](#source-pubmed-observation-pmid-39019866-2024-07-20-497b93ace79d))

## Sources

<a id="source-pubmed-observation-pmid-39019866-2024-07-20-497b93ace79d"></a>
- **Structural insights into the triple agonism at GLP-1R, GIPR and GCGR manifested by retatrutide. · retained source version 1:2024-07-20:current:497b93ace79d837dda2b256a32f24f2a382bd85111476943a7b6d1a57b056d33** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/39019866/) (`pubmed-observation-pmid-39019866-2024-07-20-497b93ace79d`)

## Correction lineage

No correction is recorded for this version.

## Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

## Suggested citation

PeptideScanner. "Structural insights into the triple agonism at GLP-1R, GIPR and GCGR manifested by retatrutide." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/objects/pubmed-pmid-39019866-retatrutide-v1.json SHA-256: c936a9e916f15ffba7e1b7f3ffc8978af24ad29ba3dd29973f95a974a2bba6cd.